Estradiol monopropionate
 | |
| Clinical data | |
|---|---|
| Trade names | Acrofollin, Akrofollin, Follhormon |
| Other names | EP; Estradiol monopropionate; Estradiol propanoate; Estradiol 17β-propionate; Estradiol 17β-propanoate; Estra-1,3,5(10)-trien-3,17β-diol 17β-propionate |
| Routes of administration | Intramuscular injection |
| Drug class | Estrogen; Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.021.059 |
| Chemical and physical data | |
| Formula | C21H28O3 |
| Molar mass | 328.452 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estradiol propionate (EP), also known as estradiol monopropionate or estradiol 17β-propionate and sold under the brand names Acrofollin, Akrofollin, and Follhormon, is an estrogen medication and estrogen ester which is no longer marketed.[1][2] It is the C17β propionate ester of estradiol.[1][2] EP was provided in an oil solution and was administered by intramuscular injection.[3][4][5][6] The medication was first marketed by 1938 or 1939.[7][8]
| Estrogen | Other names | RBA (%)a | REP (%)b | |||
|---|---|---|---|---|---|---|
| ER | ERα | ERβ | ||||
| Estradiol | E2 | 100 | 100 | 100 | ||
| Estradiol 3-sulfate | E2S; E2-3S | ? | 0.02 | 0.04 | ||
| Estradiol 3-glucuronide | E2-3G | ? | 0.02 | 0.09 | ||
| Estradiol 17β-glucuronide | E2-17G | ? | 0.002 | 0.0002 | ||
| Estradiol benzoate | EB; Estradiol 3-benzoate | 10 | 1.1 | 0.52 | ||
| Estradiol 17β-acetate | E2-17A | 31–45 | 24 | ? | ||
| Estradiol diacetate | EDA; Estradiol 3,17β-diacetate | ? | 0.79 | ? | ||
| Estradiol propionate | EP; Estradiol 17β-propionate | 19–26 | 2.6 | ? | ||
| Estradiol valerate | EV; Estradiol 17β-valerate | 2–11 | 0.04–21 | ? | ||
| Estradiol cypionate | EC; Estradiol 17β-cypionate | ?c | 4.0 | ? | ||
| Estradiol palmitate | Estradiol 17β-palmitate | 0 | ? | ? | ||
| Estradiol stearate | Estradiol 17β-stearate | 0 | ? | ? | ||
| Estrone | E1; 17-Ketoestradiol | 11 | 5.3–38 | 14 | ||
| Estrone sulfate | E1S; Estrone 3-sulfate | 2 | 0.004 | 0.002 | ||
| Estrone glucuronide | E1G; Estrone 3-glucuronide | ? | <0.001 | 0.0006 | ||
| Ethinylestradiol | EE; 17α-Ethynylestradiol | 100 | 17–150 | 129 | ||
| Mestranol | EE 3-methyl ether | 1 | 1.3–8.2 | 0.16 | ||
| Quinestrol | EE 3-cyclopentyl ether | ? | 0.37 | ? | ||
| Footnotes: a = Relative binding affinities (RBAs) were determined via in-vitro displacement of labeled estradiol from estrogen receptors (ERs) generally of rodent uterine cytosol. Estrogen esters are variably hydrolyzed into estrogens in these systems (shorter ester chain length -> greater rate of hydrolysis) and the ER RBAs of the esters decrease strongly when hydrolysis is prevented. b = Relative estrogenic potencies (REPs) were calculated from half-maximal effective concentrations (EC50) that were determined via in-vitro β‐galactosidase (β-gal) and green fluorescent protein (GFP) production assays in yeast expressing human ERα and human ERβ. Both mammalian cells and yeast have the capacity to hydrolyze estrogen esters. c = The affinities of estradiol cypionate for the ERs are similar to those of estradiol valerate and estradiol benzoate (figure). Sources: See template page. | ||||||
See also
References
- ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 898. ISBN 978-1-4757-2085-3.
- ^ a b Negwer M (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. p. 1967. ISBN 978-3-05-500156-7.
Estra-1,3,5(10)-triene-3,17β-diol 17-propionate = 3,17β-Estradiol 17-monopropionate = (17β)-Estra-1,3,5(10)-triene-3,17-diol 17-propanoate (e) S Acrofollin, Akrofollin, Estradiol monopropionate, Follhormon "Saper", Ostradiolmonopropionat, Oestrolum propionicum U Estrogen
- ^ United States. Department of the Treasury (1942). Treasury Decisions Under the Customs, Internal Revenue, and Other Laws: Including the Decisions of the Board of General Appraisers and the Court of Customs Appeals. U.S. Government Printing Office. p. 135.
[...] T. D. 50714-C, covering akrofollin intramuscular oily solution of estrogenic hormone manufactured by Specific Pharmaceuticals, Inc., New York, N. Y., with the use of imported oestradiol-17-propionate crystals, [...]
- ^ Csillag M, Vaczy L, Turr E (January 1951). "Apparent differences between the parenteral and intrauterine administration of estrogen substances". Gynaecologia. 131 (1): 9–18. doi:10.1159/000311707. PMID 14813560.
For the following two groups we have chosen estradiol propionate (Akrofollin) in a dose of 3 X 5 mg. In each instance we performed biopsic strip-abrasion on the third day after the termination of intrauterine, resp. intramuscular hormone administration.
- ^ Orosz M, Csapó I, Varga B (August 1983). "Alteration in the reactivity of hamster cheek pouch arterioles to prostaglandin E2 and noradrenaline during pregnancy or sex steroid treatment". Prostaglandins. 26 (2): 165–73. doi:10.1016/0090-6980(83)90085-0. PMID 6580678.
[...] they were treated each second day with 0.2 ml sunflower oil, 0.2 mg/lOO g bw of oestradiol propionate (Akrofollin, Richter), [...]
- ^ Wachnik A, Biró G, Biró L, Korom M, Gergely A, Antal M (1993). "Effect of sex hormones on copper, zinc, iron nutritional status and hepatic lipid peroxidation in rats". Die Nahrung. 37 (1): 28–34. doi:10.1002/food.19930370106. PMID 8464456.
injected subcutaneously with oily solution of estradiol propionate (Acrofollin, Richter Gedeon)
- ^ Boletín oficial de la propiedad industrial. Carasa y Cía. 1938.
Fecha del Fecha de la solicitud de la marca: Abril 13, 1938. Certificado de propiedad: Octubre 23, 1939. Nombre y domicilio del concesionario: Chinoin Fábrica de Productos Farmacéuticos y Química S. A., Ujpest, Hungría. AKROFOLLIN.
- ^ Dubrauszky V, St. Martzy (1941). "Die Wirkung natürlicher und künstlicher Brunststoffe im Tierversuch" [The effect of natural and artificial compounds in animal experiments]. Archiv für Gynäkologie. 171 (2): 242–253. doi:10.1007/BF01714680. ISSN 0003-9128. S2CID 9251783.